Introduction {#s1}
============

With new cases and mortality increased dramatically, cancer has become the major public health burden worldwide. For this reason, novel diagnostic markers are needed urgently for early detection and prevention of cancer. However, carcinogenesis is a complicated biological process that is not fully understood. It is generally believed that interactions of low-penetrance susceptibility genes with environmental factors might contribute to carcinogenesis [@pone.0090090-Lichtenstein1]. As one of the important low-penetrance genes, *Fas* is considered to be a potential cancer susceptibility gene. This is because Fas (TNFSF6, CD95, or APO-1) is a cell surface receptor involved in apoptotic signal transmission in many cell types and interacts with its natural ligand Fas ligand (also known as FasL) to initiate the death signal cascade that leads to apoptotic cell death [@pone.0090090-Itoh1], [@pone.0090090-Oehm1]. Furthermore, in these two genes, there are several functionally significant polymorphisms, such as the −670A\>G and −1377G\>A in the *Fas* promoter region, and the −844C\>T in the *FasL* promoter region, because they might be associated with cancer risk, including cervical cancer [@pone.0090090-Kang1]--[@pone.0090090-Lai2], gastric cancer [@pone.0090090-Zhang1]--[@pone.0090090-Hsu1], breast cancer [@pone.0090090-Hashemi1]--[@pone.0090090-Krippl1], lung cancer [@pone.0090090-TerMinassian1]--[@pone.0090090-Zhang3] and so on. However, all available results are not always consistent with one another, partially because of the small sample size of some published studies, different ethnic backgrounds, publication bias, and little effect of the polymorphisms on cancer risk. Therefore, it\'s necessary to retrieve and pool all eligible data to further determine whether these genetic polymorphisms could be at increased risk for developing cancer and to what extent heterogeneity existed across all the studies.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant studies {#s2a}
--------------------------------------------------

Two online medical databases, PubMed, and Web of Science, were searched (updated February 2013), using the search terms "Fas/CD95/TNFSF6/APO-1", "FasL/CD95L", "polymorphism/genetic variation" and "cancer/carcinoma/tumor"). The literature search was limited to English articles. In addition, more studies were also identified by manual search based on the references provided in the retrieved studies. The inclusion criteria were prespecified as below: (1) be a case-control study, (2) evaluate association between the *Fas* and/or *FasL* polymorphisms and cancer risk, (3) present sufficient data to calculate an odds ratio (OR) with 95% confidence interval (CI), and (4) list genotype frequency. Moreover, the studies without raw data, or those that were case-only studies, case reports, editorials, and review articles (including meta-analyses) were eliminated.

Data extraction {#s2b}
---------------

Information was extracted carefully from all eligible articles independently by two authors (Yeqiong Xu and Bangshun He) according to the above inclusion and exclusion criteria. Discrepancies were resolved by extensive discussion in our research team. The characteristics of enrolled studies were extracted as below: the first author\'s last name, year of publication, country of subjects, ethnicity, type of cancer, the source of controls, genotyping method (whether PCR was performed using a dual-labelled TaqMan probe with a specific 3\'base to detect the SNPs or whether an RFLP method was used), the number of matched cases and controls, polymorphism sites, and *P* value for Hardy--Weinberg equilibrium (HWE) as summarized in [Table 1](#pone-0090090-t001){ref-type="table"}.

10.1371/journal.pone.0090090.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0090090.t001){#pone-0090090-t001-1}

  Cancer type              Year                        First author                                  Country             Ethnicity   Source of control               Genotyping method                              Polymorphism sites                  Cases   Controls           HWE
  ----------------------- ------ -------------------------------------------------------- ----------------------------- ----------- ------------------- ------------------------------------------- -------------------------------------------------- ------- ---------- ---------------------
  Cervical cancer                                                                                                                                                                                                                                                         
                           2009              Zucchini [@pone.0090090-Zucchi1]              Maton Grosso do Sul, Brazil    African           PB                           PCR-RFLP                                     *Fas* -670A\>G                     91       176             0.545
                           2008         Tamandani [@pone.0090090-KordiTamandani1]                Northern India            Asian            HB                           PCR-RFLP                                     *Fas* -670A\>G                     200      200             0.001
                           2008                 Kang [@pone.0090090-Kang1]                            Korea                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    154      160      0.264, 0.233, 0.327
                           2007             Ivansson [@pone.0090090-Ivansson1]                       Sweden              Caucasian          PB                            TaqMan                                     *FasL* -844C\>T                    1284      280             0.738
                           2006                 Ueda [@pone.0090090-Ueda1]                            Japan                Asian            PB                           PCR-RFLP                                     *Fas* -670A\>G                     83        95             0.172
                           2005              Zoodsma [@pone.0090090-Zoodsma1]                      Netherlands           Caucasian          PB                            TaqMan                                      *Fas* -670A\>G                     670      607             0.274
                           2005                  Sun [@pone.0090090-Sun1]                             China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    314      615      0.641, 0.304, 0.002
                           2005                  Lai [@pone.0090090-Lai1]                             China                Asian            HB                            TaqMan                     *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    318      318      0.736, 0.293, 0.920
                           2004           Dybikowska [@pone.0090090-Dybikowska1]                     Poland              Caucasian          PB                           PCR-RFLP                                     *Fas* -670A\>G                     51        65             0.638
                           2003                  Lai [@pone.0090090-Lai2]                             China                Asian            HB                           PCR-RFLP                                     *Fas* -670A\>G                     176      176             0.444
  Gastric cancer                                                                                                                                                                                                                                                          
                           2012                Zhang [@pone.0090090-Zhang1]                           China                Asian            HB                           PCR-RFLP                            *Fas* -1377G\>A, *FasL* -844C\>T            375      496         0.064, 0.112
                           2011                  Liu [@pone.0090090-Liu1]                             China                Asian            PB                           PCR-RFLP                            *Fas* -1377G\>A, *FasL* -844C\>T            344      324         0.424, 0.083
                           2011           Kupcinskas [@pone.0090090-Kupcinskas1]                      Mixed              Caucasian          PB                            TaqMan                     *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    114      238      0.199, 0.492, 0.715
                           2010                 Zhou [@pone.0090090-Zhou1]                            China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    262      524      0.133, 0.062, 0.899
                           2009                 Wang [@pone.0090090-Wang1]                            China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    332      324      0.806, 0.870, 0.554
                           2008                  Hsu [@pone.0090090-Hsu1]                             China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    86       101      0.736, 0.914, 0.612
                           2006              Ikehara [@pone.0090090-Ikehara1]                         Japan                Asian            PB                           PCR-CTPP                                     *Fas* -670A\>G                     271      271             0.504
  Breast cancer                                                                                                                                                                                                                                                           
                           2013              Hashemi [@pone.0090090-Hashemi1]                        Iranian             Caucasian          PB                          T-ARMS-PCR                   *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    134      152      0.045, 0.000, 0.183
                           2012                 Wang [@pone.0090090-Wang2]                            China                Asian            HB                           PCR-RFLP                            *Fas* -1377G\>A, *FasL* -844C\>T            375      496         0.064, 0.112
                           2012             Mahfoudh [@pone.0090090-Mahfoudh1]                       Tunisia              African           PB                           PCR-RFLP                                    *FasL* -844C\>T                     438      332             0.334
                           2007                 Crew [@pone.0090090-Crew1]                           America             Caucasian          PB                            TaqMan                     *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T   1051      1101     0.754, 0.069, 0.602
                           2007                Zhang [@pone.0090090-Zhang2]                           China                Asian            HB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    836      834      0.797, 0.700, 0.110
                           2004               Krippl [@pone.0090090-Krippl1]                         Austria             Caucasian          PB                            TaqMan                     *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    499      495      0.924, 0.610, 0.418
  Lung cancer                                                                                                                                                                                                                                                             
                           2008        Ter-Minassian [@pone.0090090-TerMinassian1]                   America             Caucasian          HB                            TaqMan                             *Fas* -1377G\>A, *FasL* -844C\>T           2174      1497        0.751, 0.254
                           2007               Gormus [@pone.0090090-Gormus1]                         Turkey              Caucasian          PB                           PCR-RFLP                                    *Fas* -1377G\>A                     94        50             0.000
                           2006                 Park [@pone.0090090-Park1]                            Korea                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    582      582      0.132, 0.024, 0.570
                           2005                Zhang [@pone.0090090-Zhang3]                           China                Asian            PB                           PCR-RFLP                            *Fas* -1377G\>A, *FasL* -844C\>T           1000      1270        0.046, 0.180
                           2003                 Wang [@pone.0090090-Wang3]                           America               Mixed            PB                           PCR-RFLP                                     *Fas* -670A\>G                     68        74             0.481
  Esophageal cancer                                                                                                                                                                                                                                                       
                           2011                  Bye [@pone.0090090-Bye1]                    Eastern or Western Cape      African           PB                            TaqMan                     *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    343      466      0.027, 0.670, 0.097
                           2011                  Bye [@pone.0090090-Bye1]                         Western Cape             Mixed            PB                            TaqMan                     *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    195      420      0.170, 0.469, 0.741
                           2007                 Jain [@pone.0090090-Jain1]                       Northern India            Asian            PB                           PCR-RFLP                                     *Fas -670A\>G*                     151      201             0.140
                           2003                  Sun [@pone.0090090-Sun2]                             China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    588      648      0.130, 0.218, 0.061
  Skin cancer                                                                                                                                                                                                                                                             
                           2010              Qureshi [@pone.0090090-Qureshi1]                        Britain             Caucasian          PB                              NA                       *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    779      842      0.210, 0.916, 0.427
                           2007                Zhang [@pone.0090090-Zhang5]                          Sweden              Caucasian          PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    229      351      0.380, 0.009, 0.609
                           2006                   Li [@pone.0090090-Li1]                             America             Caucasian          HB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    602      603      0.453, 0.951, 0.071
                           2001               Nelson [@pone.0090090-Nelson1]                         America             Caucasian          PB                           PCR-RFLP                                     *Fas* -670A\>G                     776      435             0.117
  Ovarian cancer                                                                                                                                                                                                                                                          
                           2012                   Li [@pone.0090090-Li2]                              China                Asian            PB           Allele-specific multiple ligase detection   *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    342      344      0.357, 0.972, 0.547
                           2007               Gormus [@pone.0090090-Gormus2]                         Turkey              Caucasian          PB                           PCR-RFLP                            *Fas* -1377G\>A, *FasL* -844C\>T            47        41         0.272, 0.678
                           2006                 Ueda [@pone.0090090-Ueda1]                            Japan                Asian            PB                           PCR-RFLP                                     *Fas* -670A\>G                     68        95             0.172
  Prostate cancer                                                                                                                                                                                                                                                         
                           2012               Mandal [@pone.0090090-Mandal1]                     Northern India            Asian            HB                           PCR-RFLP                            *Fas* -670A\>G, *Fas* -1377G\>A             192      224         0.296, 0.035
                           2011                 Shao [@pone.0090090-Shao1]                            China                Asian            HB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    602      703      0.579, 0.099, 0.801
                           2008                 Lima [@pone.0090090-Lima1]                          Portugal             Caucasian          PB                           PCR-RFLP                                     *Fas* -670A\>G                     657      247             0.365
  Nasopharyngeal cancer                                                                                                                                                                                                                                                   
                           2010                  Cao [@pone.0090090-Cao1]                             China                Asian            PB                           PCR-RFLP                            *Fas* -1377G\>A, *FasL* -844C\>T            576      608         0.984, 0.015
                           2010                  Zhu [@pone.0090090-Zhu1]                             China                Asian            PB                           PCR-RFLP                                     *Fas* -670A\>G                     237      264             0.478
                           2006             Jrad [@pone.0090090-BelHadjJrad1]                        Tunisia              African           PB                           PCR-RFLP                                     *Fas* -670A\>G                     170      224             0.585
  Bladder cancer                                                                                                                                                                                                                                                          
                           2010              Gangwar [@pone.0090090-Gangwar1]                    Northern India            Asian            PB                           PCR-RFLP                                     *Fas* -670A\>G                     212      250             0.384
                           2006                   Li [@pone.0090090-Li3]                              China                Asian            HB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    216      252      0.409, 0.970, 0.234
  Other cancers                                                                                                                                                                                                                                                           
                           2010                  Zhu [@pone.0090090-Zhu2]                             China                Asian            HB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    353      365      0.831, 0.777, 0.278
                           2010                 Wang [@pone.0090090-Wang4]                            China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    294      333      0.034, 0.628, 0.271
                           2008                 Yang [@pone.0090090-Yang1]                            China                Asian            PB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    397      907      0.653, 0.062, 0.986
                           2007             Koshkina [@pone.0090090-Koshkina1]                       America               Mixed            PB                           PCR-RFLP                            *Fas* -670A\>G, *Fas* -1377G\>A             123      510         0.786, 0.210
                           2007              Erdogan [@pone.0090090-Erdogan1]                        Turkey              Caucasian          HB                           PCR-RFLP                            *Fas* -670A\>G, *FasL* -844C\>T             45       100         0.812, 0.727
                           2007   Ho[a](#nt101){ref-type="table-fn"} [@pone.0090090-Ho1]             America               Mixed            HB                           PCR-RFLP                                    *Fas* -1377G\>A                     279      510             0.210
                           2007   Ho[b](#nt101){ref-type="table-fn"} [@pone.0090090-Ho1]             America               Mixed            HB                           PCR-RFLP                                    *Fas* -1377G\>A                     154      510             0.210
                           2006                Zhang [@pone.0090090-Zhang4]                          America             Caucasian          HB                           PCR-RFLP                    *Fas* -670A\>G, *Fas* -1377G\>A, *FasL* -844C\>T    721      1234     0.481, 0.268, 0.411
                           2006                 Ueda [@pone.0090090-Ueda1]                            Japan                Asian            PB                           PCR-RFLP                                     *Fas* -670A\>G                     108       95             0.172

The Ho(^a^) investigated thyroid cancer, and the Ho(^b^) investigated salivary gland cancer.

PB: population based; HB: hospital based; T-ARMS-PCR:tetra-primeramplification refractory mutation system PCR; PCR-RFLP: restriction fragment length polymorphism; HWE: Hardy-Weinberg equilibrium.

Genotype-gene expression correlation analysis {#s2c}
---------------------------------------------

The International HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/>) was used to obtain data of the *Fas* and *FasL* genotypes determined in 270 enrolled subjects. Meanwhile, the mRNA expression data of these enrolled subjects were available online from SNPexp (<http://app3.titan.uio.no/biotools/help.php?app=snpexp>) as described in the previous studies [@pone.0090090-Holm1], [@pone.0090090-He1]. In brief, these data were obtained from the HapMap phase II release 23 data set consisting of 3.96 million SNP genotypes from 270 subjects of three populations, including 90 European (CEU), 90 Asian (45 Chinese, 45 Japanese), and 90 Yoruba (YRI) subjects [@pone.0090090-1]. Additionally, the mRNA expression data were derived from the lymphoblastic cell lines from the same 270 subjects [@pone.0090090-Stranger1].

Statistical analysis {#s2d}
--------------------

Crude ORs with 95% CIs were used to assess the strength of association between the polymorphisms in *Fas*-670A\>G, *Fas* -1377G\>A, and *FasL* -844T/C and cancer risk. The pooled ORs were estimated for dominant model (variant homozygotes + heterozygous vs homozygous reference), recessive model (variant homozygotes vs heterozygous + homozygous reference), homozygote comparison (variant homozygotes vs homozygous reference), heterozygote comparison (heterozygous vs homozygous reference) and allelic comparison in the polymorphisms, respectively. Stratified analyses were performed by the type of cancer (that with only one study was grouped together as 'other cancers'), ethnicity, source of controls and genotyping method. Heterogeneity across the studies was evaluated by using the Chi-square test based Q-statistic test, and it was considered statistically significant when *P~heterogeneity~* (*P~h~*)\<0.05. The data were combined using random-effects model (the DerSimonian and Laird method) [@pone.0090090-DerSimonian1] in the presence of heterogeneity (*P*\<0.05 or *I^2^*\>50%), or fixed-effects model (the Mantel-Haenszel method) models [@pone.0090090-Mantel1] was chosen to use in the absence of heterogeneity (*P*\>0.05 or *I^2^*\<50%). Moreover, sensitivity analyses were performed to assess the stability of the results. Publication bias was evaluated graphically by using funnel plots and statistically by the Egger\'s linear regression test. HWE of the three polymorphisms was assessed using a web-based program (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). All statistical tests were performed with STATA 11.0 and SPSS 20.0. All the *P* values were two-sided.

Results {#s3}
=======

A total of 52 studies were enrolled in this meta-analysis ([Figure 1](#pone-0090090-g001){ref-type="fig"}). The major characteristics of the 52 selected studies are summarized in [Table 1](#pone-0090090-t001){ref-type="table"}. The study carried out by Bye et al [@pone.0090090-Bye1] analyzed individuals of African or Mixed ethnicity, and thus was divided into two studies. Similarly, the studies reported by Ho et al [@pone.0090090-Ho1] and Ueda et al [@pone.0090090-Ueda1] investigated two and three types of cancer, and therefore, these two studies were cited as two studies and three studies, respectively ([Table 1](#pone-0090090-t001){ref-type="table"}).

![Flow chart of studies identified according to inclusion and exclusion criteria.](pone.0090090.g001){#pone-0090090-g001}

For the *Fas* -670A\>G polymorphism, there was no association in the pooled analysis. In the subgroup analysis, statistically significantly decreased risk was observed in prostate cancer and melanoma for GG+AG vs AA comparison model, whereas there was significantly increased risk among those of African ancestry for GG+AG vs AA models (all data shown in [Table 2](#pone-0090090-t002){ref-type="table"}).

10.1371/journal.pone.0090090.t002

###### Stratified analyses of the *Fas* -670A\>G (rs1800682) polymorphism and cancer.

![](pone.0090090.t002){#pone-0090090-t002-2}

  Variables               n[a](#nt103){ref-type="table-fn"}                     GG+AG vs AA                      GG vs AG+AA   G vs A                                                                                                                              
  ---------------------- ----------------------------------- -------------------------------------------------- ------------- -------- -------------------------------------------------- ------- ------ ------------------------------------------------- ------- ------
  Total                                  44                   1.01(0.94, 1.09)[c](#nt105){ref-type="table-fn"}    \<0.0001      47.1    1.04(0.96, 1.12)[c](#nt105){ref-type="table-fn"}   0.003   40.9   1.02(0.97,1.06)[c](#nt105){ref-type="table-fn"}   0.005   39.4
  Cancer type                                                                                                                                                                                                                                                      
  Cervical cancer                         9                   1.05(0.79,1.40)[c](#nt105){ref-type="table-fn"}     \<0.0001      74.5    0.92(0.69, 1.22)[c](#nt105){ref-type="table-fn"}   0.006   62.8   0.99(0.86,1.14)[c](#nt105){ref-type="table-fn"}   0.013   58.5
  Gastric cancer                          5                                   1.08(0.91,1.28)                       0.340       11.6                    0.97(0.79,1.21)                    0.978   0.0                    1.03(0.91,1.15)                   0.735   0.0
  Esophageal cancer                       4                                   1.02(0.85,1.21)                       0.459       0.0     1.21(0.86,1.69)[c](#nt105){ref-type="table-fn"}    0.017   70.4                   1.10(0.99,1.23)                   0.215   32.9
  Breast cancer                           4                                   1.01(0.90,1.14)                       0.325       13.4                    1.03(0.90,1.18)                    0.062   59.1                   1.02(0.94,1.10)                   0.259   25.5
  Prostate cancer                         3                                 **0.83(0.70,0.98)**                     0.155       46.4                    0.82(0.66,1.01)                    0.346   5.8                    0.87(0.77,0.97)                   0.163   44.8
  Ovarian cancer                          2                                   0.87(0.66,1.15)                       0.952       0.0                     0.85(0.57,1.28)                    0.622   0.0                    0.90(0.74,1.09)                   0.745   0.0
  Bladder cancer                          2                                   1.01(0.77,1.33)                       0.588       0.0     1.00(0.47,2.16)[c](#nt105){ref-type="table-fn"}    0.043   75.6                   1.03(0.85,1.24)                   0.491   0.0
  Skin cancer                             2                                   1.08(0.91,1.27)                       0.414       0.0                     1.02(0.86,1.23)                    0.483   0.0                    1.04(0.93,1.16)                   0.902   0.0
  Nasopharyneal cancer                    2                   1.55(0.75,3.24)[c](#nt105){ref-type="table-fn"}       0.017       82.4    1.39(0.69,2.79)[c](#nt105){ref-type="table-fn"}    0.042   75.8   1.33(0.80,2.19)[c](#nt105){ref-type="table-fn"}   0.008   85.6
  Melanoma                                2                                 **0.79(0.64,0.97)**                     0.765       0.0                     0.96(0.77,1.21)                    0.790   0.0                    0.90(0.78,1.02)                   0.725   0.0
  Lung cancer                             2                                   0.82(0.65,1.04)                       0.852       0.0                     1.07(0.82,1.40)                    0.906   0.0                    0.94(0.81,1.10)                   0.984   0.0
  Other cancers                           7                                   1.08(0.96,1.22)                       0.373       7.3                     1.15(0.99,1.32)                    0.747   0.0                    1.08(1.00,1.17)                   0.528   0.0
  Ethnicity                                                                                                                                                                                                                                                        
  Asian                                  25                   0.97(0.88,1.06)[c](#nt105){ref-type="table-fn"}       0.004       48.3    1.01(0.89, 1.15)[c](#nt105){ref-type="table-fn"}   0.003   49.3   0.99(0.93,1.05)[c](#nt105){ref-type="table-fn"}   0.030   37.8
  Caucasian                              13                                   1.03(0.95, 1.12)                      0.120       32.8                    1.00(0.92, 1.09)                   0.277   16.5                   1.01(0.96,1.06)                   0.277   16.6
  African                                 3                                 **1.72(1.24,2.38)**                     0.288       19.6    1.23(0.78,1.95)[c](#nt105){ref-type="table-fn"}    0.039   69.1   1.25(0.90,1.74)[c](#nt105){ref-type="table-fn"}   0.022   73.9
  Mixed                                   3                                   1.10(0.82, 1.48)                      0.607       0.0                     1.28(0.99, 1.65)                   0.803   0.0                    1.15(0.97,1.37)                   0.610   0.0

Number of comparisons.

*P* value of *Q*-test for heterogeneity test.

Random-effect model was applied when P value for heterogeneity \< 0.05; otherwise, fixed-effect model was applied.

Statistically significant results were in bold.

For *Fas* -1377G\>A polymorphism, significantly increased cancer risks were observed in AA vs GG ([Figure 2](#pone-0090090-g002){ref-type="fig"}) and AA vs GA+GG comparison models in the overall analysis. In the subgroup analysis by cancer type, a significantly increased risk was observed in breast cancer for all comparison models. Meanwhile, increased risks were found for the comparison of AA vs GG and AA vs GA+GG in gastric cancer and esophageal cancer. In addition, a borderline decreased cancer risk was found in melanoma for GA vs GG and AA+GA vs GG comparison models (all data shown in [Table 3](#pone-0090090-t003){ref-type="table"}).

![Forest plots of effect estimates for *Fas* -1377G\>A polymorphism (AA vs GG).\
For each of the studies, the estimation of OR and its 95% CI is plotted with a *box* and a *horizontal line*. *Filled diamond* pooled OR and its 95% CI.](pone.0090090.g002){#pone-0090090-g002}

10.1371/journal.pone.0090090.t003

###### Stratified analyses of the *Fas* -1377G\>A (rs2234767) polymorphism and cancer.

![](pone.0090090.t003){#pone-0090090-t003-3}

  Variables            n[a](#nt107){ref-type="table-fn"}                         AA vs GG                          GA vs GG   AA+GA vs GG                     AA vs GA+GG                     A vs G                                                                                                                                                                                                                
  ------------------- ----------------------------------- ------------------------------------------------------- ---------- ------------- ------------------------------------------------- -------- ------ ------------------------------------------------- ------- ------ ------------------------------------------------------- ------- ------ ------------------------------------------------------ ------- ------
  Total                               37                   **1.19(1.06, 1.34)** [c](#nt109){ref-type="table-fn"}    0.024        34.7       1.00(0.94,1.06)[c](#nt109){ref-type="table-fn"}   0.033    32.2   1.03(0.97,1.10)[c](#nt109){ref-type="table-fn"}   0.012   37.8   **1.21(1.09, 1.34)** [c](#nt109){ref-type="table-fn"}   0.048   30.3   **1.06(1.00,1.11)** [c](#nt109){ref-type="table-fn"}   0.002   44.8
  Cancer type                                                                                                                                                                                                                                                                                                                                                                                                       
  Gastric cancer                       6                                   **1.31(1.05, 1.65)**                     0.934         0.0                       0.99(0.85,1.14)                   0.810    0.0                    1.04(0.91,1.20)                   0.659   0.0                     **1.32(1.07,1.64)**                    0.328   13.6                     1.09(0.99,1.21)                      0.372   7.0
  Breast cancer                        5                                    **1.39(1.12,1.72)**                     0.420         0.0                     **1.15(1.02,1.30)**                 0.246    26.3                 **1.18(1.06,1.32)**                 0.253   25.3                    **1.28(1.05,1.56)**                    0.236   27.8                   **1.15(1.06,1.26)**                    0.186   35.3
  Lung cancer                          4                      1.18(0.82,1.70)[c](#nt109){ref-type="table-fn"}       0.050        66.6                       0.97(0.87,1.08)                   0.743    0.0                    1.01(0.91,1.12)                   0.687   0.0       1.23(0.86,1.74)[c](#nt109){ref-type="table-fn"}      0.044   68.0                     1.06(0.97,1.14)                      0.279   21.8
  Esophageal cancer                    3                                    **1.42(1.03,1.96)**                     0.106        55.4       0.96(0.66,1.37)[c](#nt109){ref-type="table-fn"}   0.031    71.2   1.00(0.72,1.39)[c](#nt109){ref-type="table-fn"}   0.043   68.1                    **1.58(1.16,2.13)**                    0.089   58.7     1.05(0.76,1.45)[c](#nt109){ref-type="table-fn"}      0.022   73.8
  Cervical cancer                      3                                     0.95(0.70, 1.28)                       0.201        37.6                       0.85(0.70,1.04)                   0.149    47.4                   0.88(0.73,1.06)                   0.165   44.6                      1.08(0.81,1.42)                      0.215   35.0                     0.95(0.83,1.09)                      0.195   38.8
  Prostate cancer                      2                                      0.82(0.61,1.10)                       0.199        39.5       0.91(0.53,1.54)[c](#nt109){ref-type="table-fn"}   0.042    75.9   0.90(0.54,1.50)[c](#nt109){ref-type="table-fn"}   0.042   75.8                      0.91(0.70,1.19)                      0.698   0.0                      0.88(0.77,1.01)                      0.099   63.2
  Ovarian cancer                       2                                      0.91(0.54,1.52)                         NA          NA                        1.04(0.77,1.40)                   0.286    12.1                   1.02(0.77,1.36)                   0.270   17.9                      0.91(0.56,1.50)                       NA      NA                      1.00(0.80,1.24)                      0.308   3.8
  Melanoma                             2                                      0.74(0.37,1.46)                       0.645         0.0                     **0.79(0.62,1.00)**                 0.614    0.0                  **0.78(0.62,0.98)**                 0.748   0.0                       0.77(0.39,1.52)                      0.617   0.0                    **0.80(0.65,0.98)**                    0.916   0.0
  Other cancers                       10                                    **1.32(1.12,1.56)**                     0.327        12.5                       1.07(0.97,1.17)                   0.437    0.0                  **1.10(1.01,1.21)**                 0.364   8.5                     **1.28(1.10,1.49)**                    0.351   10.0                   **1.12(1.04,1.20)**                    0.244   21.7

Number of comparisons.

*P* value of *Q*-test for heterogeneity test.

Random-effect model was applied when P value for heterogeneity \<0.05; otherwise, fixed-effect model was applied.

Statistically significant results were in bold.

For *FasL* -844C\>T polymorphism, significantly increased cancer risks were observed in CC vs TT ([Figure 3](#pone-0090090-g003){ref-type="fig"}), CC+CT vs TT and CC vs CT+TT in the overall analysis. When the analysis was stratified by genotyping method, an increased cancer risk was observed in studies carried out by PCR-RFLP (shown in [Table 4](#pone-0090090-t004){ref-type="table"}).

![Forest plots of effect estimates for *FasL*-844C\>T polymorphism (CC vs TT).\
For each of the studies, the estimate of OR and its 95% CI is plotted with a *box* and a *horizontal line*. *Filled diamond* pooled OR and its 95% CI.](pone.0090090.g003){#pone-0090090-g003}

10.1371/journal.pone.0090090.t004

###### Stratified analyses of the *FasL*-844C\>T (rs763110) polymorphism and cancer.

![](pone.0090090.t004){#pone-0090090-t004-4}

  Variables    n[a](#nt112){ref-type="table-fn"}                         CC vs TT                          CT vs TT   CC+CT vs TT     CC vs CT+TT     C vs T                                                                                                                                                                                                                           
  ----------- ----------------------------------- ------------------------------------------------------- ---------- ------------- ----------------- -------- ------ ------------------------------------------------------ ------- ------ ------------------------------------------------------- ---------- ------ ------------------------------------------------------ ---------- ------
  Total                       35                   **1.19(1.06, 1.35)** [c](#nt114){ref-type="table-fn"}   \<0.0001      53.0       1.02(0.95,1.09)   0.135    21.2   **1.09(1.00,1.20)** [c](#nt114){ref-type="table-fn"}   0.046   30.6   **1.20(1.08, 1.34)** [c](#nt114){ref-type="table-fn"}   \<0.0001   81.3   **1.13(1.05,1.22)** [c](#nt114){ref-type="table-fn"}   \<0.0001   78.2
  Genotype                                                                                                                                                                                                                                                                                                                                                                             
  PCR-RFLP                    24                   **1.28(1.09,1.51)** [c](#nt114){ref-type="table-fn"}     0.001        53.4       0.97(0.88,1.08)   0.113    26.8                   **1.14(1.03,1.25)**                    0.063   32.7   **1.30(1.13,1.49)** [c](#nt114){ref-type="table-fn"}    \<0.0001   83.3   **1.19(1.08,1.31)** [c](#nt114){ref-type="table-fn"}   \<0.0001   79.6
  TaqMan                       8                                      1.04(0.92,1.18)                       0.758         0.0       1.10(0.98,1.23)   0.842    0.0                      1.07(0.97,1.19)                      0.793   0.0                       0.97(0.89,1.06)                       0.839     0.0                      1.01(0.95,1.07)                       0.761     0.0

PCR-RFLP: restriction fragment length polymorphism.

Number of comparisons.

*P* value of *Q*-test for heterogeneity test.

Random-effect model was applied when P value for heterogeneity \<0.05; otherwise, fixed-effect model was applied.

Statistically significant results were in bold.

Overall effects for alleles {#s3a}
---------------------------

Allele comparisons were also conducted in the meta-analysis. However, no significant associations were found in *Fas* -670A\>G polymorphism and cancer risks (shown in [Table 2](#pone-0090090-t002){ref-type="table"}).

There was borderline association between *Fas* -1377G\>A polymorphism and cancer risks for A allele vs G allele in the overall analysis. In the subgroup analysis by cancer type, opposite results were shown between breast cancer and melanoma (shown in [Table 3](#pone-0090090-t003){ref-type="table"}).

For *FasL* -844C\>T polymorphism, in the subgroup analysis of genotyping method, an increased cancer risk was found in the studies carried out by PCR-RFLP (shown in [Table 4](#pone-0090090-t004){ref-type="table"}).

The *Fas* and *FasL* mRNA expression by genotypes and population {#s3b}
----------------------------------------------------------------

The *Fas* and *FasL* mRNA expression levels were stratified by genotype (shown in [Table 5](#pone-0090090-t005){ref-type="table"}) and population (shown in [Table 6](#pone-0090090-t006){ref-type="table"}) groups. In the genotype subgroup analysis, significant associations between mRNA expression levels and *Fas* -670A\>G were observed in all populations (GA: *P* = 0.043), especially in Asian population (GG: *P* = 0.0003; dominant: *P* = 0.003; recessive: *P* = 0.001). Meanwhile, significant differences between mRNA expression levels and *FasL* -844C\>T were observed in Asian population (recessive: *P* = 0.001). In the population-subgroup analysis, decreased expression of Fas was found in YRI (Yoruba in Ibadan) population than in the CEU population (*P* = 0.002).

10.1371/journal.pone.0090090.t005

###### *Fas* and *FasL* mRNA expression by the genotypes of SNPs, using data from the HapMap[1](#nt117){ref-type="table-fn"}.

![](pone.0090090.t005){#pone-0090090-t005-5}

  *Fas* -670A\>G                           *FasL* -844C\>T                                                                                                       
  --------------------------------------- ----------------- ----- ----------- ------------ --------------------------------------- ----------- ----- ----------- -----------
  CEU[3](#nt119){ref-type="table-fn"}            AA          23    8.79±0.36                 CEU[3](#nt119){ref-type="table-fn"}       CC       76    5.94±0.07  
                                                 GA          46    8.87±0.28     0.321                                                 CT        5    5.89±0.07     0.137
                                                 GG          12    8.74±0.36     0.687                                                 TT        0       ---         ---
                                              Dominant       58    8.84±0.30     0.511                                              Dominant     5    5.89±0.07     0.137
                                              Recessive      69    8.84±0.31     0.292                                              Recessive   81       ---         ---
  YRI[3](#nt119){ref-type="table-fn"}            AA           6    8.58±0.33                 YRI[3](#nt119){ref-type="table-fn"}       CC        0       ---         ---
                                                 GA          25    8.70±0.31     0.402                                                 CT       28    5.94±0.06      ---
                                                 GG          53    8.67±0.30     0.450                                                 TT       53    5.95±0.06      ---
                                              Dominant       78    8.58±0.33     0.410                                              Dominant    81    5.95±0.06      ---
                                              Recessive      31    8.67±0.31     0.987                                              Recessive   28    5.94±0.06     0.493
  Asian[3](#nt119){ref-type="table-fn"}          AA          28    8.65±0.29                Asian[3](#nt119){ref-type="table-fn"}      CC        0       ---         ---
                                                 GA          36    8.78±0.26     0.059                                                 CT       50    5.96±0.06      ---
                                                 GG          21    8.98±0.30   **0.0003**                                              TT       33    5.91±0.06      ---
                                              Dominant       57    8.85±0.29   **0.003**                                            Dominant    83    5.94±0.06      ---
                                              Recessive      64    8.72±0.28   **0.001**                                            Recessive   50    5.96±0.06   **0.001**
  All[3](#nt119){ref-type="table-fn"}            AA          57    8.70±0.33                 All[3](#nt119){ref-type="table-fn"}       CC       76    5.94±0.07  
                                                 GA          107   8.80±0.28   **0.043**                                               CT       83    5.95±0.06     0.163
                                                 GG          86    8.76±0.33     0.297                                                 TT       86    5.94±0.06     0.913
                                              Dominant       193   8.78±0.30     0.081                                              Dominant    169   5.95±0.06     0.390
                                              Recessive      164   8.76±0.30     0.871                                              Recessive   159   5.95±0.06   \<0.0001

CEU: 90 Utah residents with ancestry from northern and western Europe; YRI: 90 Yoruba in Ibadan, Nigeria; Asian: 45 unrelated Han Chinese in Beijing and 45 unrelated Japanese in Tokyo.

Genotyping data and mRNA expression levels for *Fas* and *FasL* by genotypes were obtained from the HapMap phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals.

Two-side Student\'s *t* test within the stratum was used.

There were missing data for unavailable genotyping data.

Statistically significant results were in bold.

10.1371/journal.pone.0090090.t006

###### *Fas* and *FasL* mRNA expression by the ethnicity, using data from the HapMap[1](#nt122){ref-type="table-fn"}.

![](pone.0090090.t006){#pone-0090090-t006-6}

  *Fas* -670A\>G                           *FasL* -844C\>T                                                                                   
  --------------------------------------- ----------------- ----------- ----------- --------------------------------------- ---- ----------- -------
  CEU[3](#nt124){ref-type="table-fn"}            81          8.83±0.31                CEU[3](#nt124){ref-type="table-fn"}    81   5.94±0.07  
  YRI[3](#nt124){ref-type="table-fn"}            84          8.67±0.30   **0.002**    YRI[3](#nt124){ref-type="table-fn"}    81   5.95±0.06   0.120
  Asian[3](#nt124){ref-type="table-fn"}          85          8.79±0.30     0.391     Asian[3](#nt124){ref-type="table-fn"}   83   5.94±0.06   0.398

CEU: 90 Utah residents with ancestry from northern and western Europe; YRI: 90 Yoruba in Ibadan, Nigeria; Asian: 45 unrelated Han Chinese in Beijing and 45 unrelated Japanese in Tokyo.

Genotyping data and mRNA expression levels for *Fas* and *FasL* by genotypes were obtained from the HapMap phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals.

Two-side Student\'s *t* test within the stratum was used.

There were missing data for unavailable genotyping data.

Statistically significant results were in bold.

Test of heterogeneity {#s3c}
---------------------

There was significant heterogeneity across the studies focused on these three polymorphisms as evaluated by Q-test. Then, we evaluated the heterogeneity for dominant model comparison by subgroups (cancer type, ethnicity, source of controls and genotyping method). As a result, ethnicity (*χ^2^* = 13.44, degree of freedom  = 3, *P~h~* = 0.004) and cancer type (*χ^2^* = 22.26, degree of freedom  = 11, *P~h~* = 0.022), but not source of controls (*χ^2^* = 1.49, degree of freedom  = 1, *P~h~* = 0.222) or genotyping method (*χ^2^* = 1.48, degree of freedom  = 4, *P~h~* = 0.830) contributed to substantial heterogeneity of the *Fas* -670A\>G polymorphism. For the *Fas* -1377G\>A polymorphism, the test revealed cancer type (*χ^2^* = 22.60, degree of freedom = 8, *P~h~* = 0.004), but not ethnicity (*χ^2^* = 4.81, degree of freedom = 3, *P~h~* = 0.187), source of controls (*χ^2^* = 0.42, degree of freedom = 1, *P~h~* = 0.518), or genotyping method (*χ^2^* = 0.51, degree of freedom = 3, *P~h~* = 0.917) contributed to substantial heterogeneity. For the *FasL* -844C\>T polymorphism, genotyping method (*χ^2^* = 9.21, degree of freedom = 3, *P~h~* = 0.027), but not cancer type (*χ^2^* = 4.33, degree of freedom = 7, *P~h~* = 0.741), ethnicity (*χ^2^* = 5.64, degree of freedom  = 3, *P~h~* = 0.131), or source of controls (*χ^2^* = 0.08, degree of freedom  = 1, *P~h~* = 0.777) contributed to substantial heterogeneity.

Sensitivity analyses {#s3d}
--------------------

To assess the stability of the results and the source of the heterogeneity, sensitivity analysis was performed by sequential removal of each individual eligible study. For *Fas* -670A\>G and *FasL* -844C\>T polymorphisms, statistically similar results were observed after sequential removal of individual study in dominant and homozygote model, respectively, and the summary ORs in the other genetic models were not materially altered, suggesting that the results were stable. For the *Fas* -1377G\>A polymorphism, sensitivity analysis indicated that study by Shao et al [@pone.0090090-Shao1] was responsible for heterogeneity. The heterogeneity was decreased when this study was removed (AA+GA vs GG: *P~h~* = 0.075, *I^2^* = 26.5). Although the genotype distribution in 11 studies (listed in [Table 1](#pone-0090090-t001){ref-type="table"}) didn\'t follow HWE, the corresponding summary ORs were not materially altered with or without including these studies for the three polymorphisms. In addition, no other single study altered the pooled ORs by sensitivity analysis.

Publication bias {#s3e}
----------------

To assess the publication bias, Begg\'s funnel plot and Egger\'s test were performed and the shapes of funnel plots didn\'t show any obvious asymmetry in all genetic models of the three polymorphisms ([Figure 4A--C](#pone-0090090-g004){ref-type="fig"}). Therefore, to provide statistical evidence of funnel plot symmetry, Egger\'s test was performed for each of these polymorphisms and the results confirmed the absence of publication bias (*P*\>0.05).

![Begg\'s funnel plot of Egger\'s test for publication bias for three polymorphisms.\
Each circle represents as an independent study for the indicated association. Log\[OR\], natural logarithm of OR. Horizontal lines mean effect size. A: Begg\'s funnel plot of publication bias test for *Fas* -670A\>G polymorphism. B: Begg\'s funnel plot of publication bias test for *Fas* -1377G\>A polymorphism. C: Begg\'s funnel plot of publication bias test for *FasL* -844C\>T polymorphism.](pone.0090090.g004){#pone-0090090-g004}

Discussion {#s4}
==========

Fas, a potent member of the death receptor family, plays a crucial role in apoptotic signaling in many cell types [@pone.0090090-Andera1]. Meanwhile, interactions between Fas and its receptor FasL trigger the death signal cascade, and subsequently induce apoptotic cell death [@pone.0090090-Kim1]. Previous studies have indicated that down-regulation of Fas expression and/or up-regulation of FasL expression could be detected in many types of human tumors [@pone.0090090-Rabinowich1], [@pone.0090090-CrnogoracJurcevic1]. The reason may be that down-regulation of Fas could protect tumor cells from elimination by anti-tumor immune responses, whereas up-regulation of FasL could increase the ability of tumor cells to counterattack the immune system by inducing apoptosis [@pone.0090090-Griffith1], [@pone.0090090-Strand1], [@pone.0090090-Reichmann1]. Therefore, it is believed that *Fas* and *FasL* play a crucial role in carcinogenesis. Given the important roles of *Fas* and *FasL* in carcinogenesis process, it is biologically plausible that *Fas* and *FasL* polymorphisms that possess the potential to influence the expression of Fas and/or FasL may be associated with cancer risk. Therefore, associations between the *Fas* -670A\>G, *Fas* -1377G\>A and *FasL* -844C\>T polymorphisms and cancer risk were determined in this meta-analysis.

In this meta-analysis, 52 published studies were enrolled to determine the association between the three potentially functional polymorphisms within the *Fas* and *FasL* and cancer risk. This study revealed that the *Fas* -1377G\>A and *FasL* -844C\>T, but not the *Fas* -670A\>G polymorphisms were associated with significantly increased overall cancer risk. Previous studies have identified that the -1377A allele had markedly reduced ability to bind transcription factor stimulatory protein 1 as compared with the -1377G allele, whereas the -670A and G alleles had similar ability to bind transcription factor signal transducers and activators of transcription 1 (STAT1)[@pone.0090090-Sibley1]. As the *Fas* -1377A allele reduced the ability to bind transcription factor stimulatory protein 1 that is a crucial transcriptional activator, the expression of Fas was decreased in carriers of the *Fas* -1377AA genotype as expected, but the *Fas* -670G allele didn\'t influence the expression of Fas [@pone.0090090-Sibley1], [@pone.0090090-Huang1]. Therefore, it is reasonable that the *Fas* -1377A allele increased the overall cancer risk, and that the *Fas* -670G allele had no marked effect on overall cancer risk, which was consistent with our results. For the *FasL* -844T\>C polymorphism, which is located in a binding motif for transcription factor CAAT/enhancer binding protein β, could influence the promoter activity of the *FasL* gene [@pone.0090090-Wu1]. Additionally, it has been proposed that compared with the -844T allele, -844C allele strongly increased the expression of FasL on T cells and was associated with an enhanced rate of activation-induced cell death of T cells, which may lead to less powerful immune surveillance and increase the susceptibility to cancer [@pone.0090090-Sun1].

The *Fas* -670GG genotype was associated with decreased risk of prostate cancer and melanoma according to the cancer type subgroup analysis. It was suggested that *Fas* -670A\>G polymorphism might have the same effect on these two cancers. However, these results were based on 44 studies, which could affect the results owing to small amount of studies. Therefore, to draw a more precise conclusion, more related studies are needed.

For the *Fas* -1377G\>A polymorphism, this study revealed that those who carried the -1377AA genotype had an increased risk for breast cancer, gastric cancer and esophageal cancer, while the melanoma risk was decreased. As described above, the different risk factors could contribute to the discrepancies. Also other unidentified causal genes would influence the effect of this polymorphism on different cancers.

For the *FasL* -844C\>T polymorphism, the -844CC associated with increased cancer risk was observed in gastric cancer, esophageal cancer, and ovarian cancer among the previous studies, indicating that this polymorphism had similar effect on these three cancers. Although these cancers had different mechanisms of carcinogenesis, small amount of studies, publication bias, and other unidentified causal genes would be the result of the discrepancies, which contributed to the similar association between the *FasL* -844C\>T polymorphism and three cancers.

In the subgroup analysis by ethnicity, an increased cancer risk in carriers of the *Fas* -670GG genotype was found in African, while the result of mRNA expression showed that GG genotype expressed higher levels of Fas in Asian populations. Meanwhile, the previous studies showed increased cancer risk in carriers of the *Fas* -1377AA and *FasL* -844CC genotype were found in Asian subjects, which was evidenced in mRNA expression by genotypes in Asian populations. However, this association was not proved in other ethnicities. The discrepancies in racial backgrounds and environment they lived in would lead to the differences. In addition, these polymorphisms might be masked by the presence of other unidentified causal genes involved in carcinogenesis. Due to the small size of population for the ethnicities, well-designed, large randomized case-control studies should be performed.

The pooled results of this study may be affected by polymorphism genotyping methods applied in the enrolled studies. Previous studies revealed that the pooled results of the *Fas* -670A\>G polymorphism were not affected by the studies with genotyping methods of both PCR-RFLP and TaqMan. While *Fas* -1377AA genotype carriers increased cancer risk in the studies using PCR-RFLP but not TaqMan, and similar result was found in the *FasL* -844CC genotype carrier. The discrepancy across the studies applied different polymorphism genotyping methods may result from the different sensitivity and accuracy of genotyping methods. Meanwhile, the quality control is crucial to cause discrepancy as well. In general, studies [@pone.0090090-Liu1], [@pone.0090090-Wang2], [@pone.0090090-Shao2] selected 10% repeated, random sample of subjects to test twice by standard genotyping method or different investigator, which was used to confirm the accuracy of results, while Mandal et al [@pone.0090090-Mandal1] and Ter-Minassian et al [@pone.0090090-TerMinassian1] tested 5% repeated samples. As a result, the consistency rate of quality control was 100% in almost all studies. However, the study by Crew et al [@pone.0090090-Crew1] showed that the consistency rate was 100% for *Fas* -1377G\>A, 94% for *Fas* -670G\>A and 96% for *FasL* -844C\>T. Therefore, the results of further studies should be confirmed by a standardized genotyping method. In addition, the limited amount of studies would also contribute to the discrepancy.

Heterogeneity is an important factor which can interpret the results of the meta-analysis. Therefore, we stratified the studies by cancer type, ethnicity, source of controls and genotyping method, respectively. The results showed that the main heterogeneity existed for cancer type and ethnicity. The reason might be that different cancers have different mechanisms of carcinogenesis. Virus infections, hormone levels, smoking, drinking, family history all could contribute to the different cancers. Meanwhile, different genetic backgrounds and different environmental factors among different ethnicities were the main factor of heterogeneity as well. Geographic differences, exposure of the Sun, eating habits, and environmental pollutes could exist in different ethnicities, which contributed to the heterogeneity.

Some limitations of the meta-analysis should be addressed. First, only studies in English were enrolled in this meta-analysis, which might miss some studies in other languages consistent with inclusion criteria. Second, some eligible studies included in the meta-analysis were hospital-based controls, which could generate the selection bias. Third, only a limited amount of studies was included, which might limit the strength of the associations. Finally, some suspected factors such as drinking, smoking, age, sex, and living habits were not considered in the meta-analysis. Regardless of such limitations, this meta-analysis still had some strengths. We investigated heterogeneity that may result from ethnicity of subjects, the types of cancer, the source of control subjects, and various genotyping methods. In addition, we analyzed the relationship between the mRNA expressions and genotypes, which partly supported the results of this meta-analysis.

In summary, this meta-analysis indicates that the *Fas*-1377G\>A and *FasL* -844T/C polymorphisms are associated with increased cancer risk, but that no significant association is observed for the *Fas* -670A\>G polymorphism and cancer risk. A definite conclusion should be made in the future through well-designed, unbiased, powered, population-based case--control association studies.
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